Push­ing mR­NA ther­a­peu­tics for can­cer, Cam­bridge start­up nabs Se­ries A to ex­plore next-gen ap­proach

With in­creased in­ter­est in mR­NA ther­a­peu­tics thanks to Pfiz­er and Mod­er­na’s megablock­buster Covid-19 vac­cines, a new start­up lo­cat­ed next to MIT is get­ting in­fused with cash as it looks to go in­to the clin­ic.

Ker­nal Bio put out word Thurs­day morn­ing that it had com­plet­ed a $25 mil­lion Se­ries A round, led by Hum­ming­bird Ven­tures. The new cap­i­tal, which should last Ker­nal about two and a half years, will ex­tend Ker­nal’s “mR­NA 2.0” plat­form and sup­port an IND fil­ing for Ker­nal’s I/O can­di­date KR-335.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER